Suits Target Endo, Actavis Over Lidoderm Pay-For-Delay

Law360, Washington (November 13, 2013, 1:26 PM EST) -- Endo Pharmaceuticals Inc. and Actavis Inc. have been hit with two putative class actions in the past week in Pennsylvania and California federal courts over their patent settlement that allegedly delayed generic competition for Endo's pain relief patch Lidoderm.

Puerto Rican pharmaceutical wholesaler Drogueria Betances launched its antitrust class action Friday in Pennsylvania, and a union health and welfare fund filed a similar complaint Tuesday in California, both alleging that Endo, Actavis and their subsidiaries unlawfully restricted Lidoderm competition with their so-called pay-for-delay deal. That agreement...
To view the full article, register now.